Following up on their decision to integrate R&D into a single organization — joining discovery and development under one chief — Germany’s Bayer is scrutinizing its research group with an eye to streamlining its operations.
Germany’s Wirtschaftswoche first reported that the German company was reviewing its R&D locations with cuts in mind, citing fears of 1,000 job cuts.
A spokesperson for Bayer tells Endpoints News, though, that the company continuously looks at its productivity and efficiency. Now it’s looking at the best way to create one “seamless” R&D operation. As for the R&D review: “Nothing has been decided yet.”
Bayer does have a name for the project, though. It’s called Super Bowl.
It all got underway late last year after Andreas Busch, the head of discovery, left Bayer to join Shire — about to be taken over by Takeda — as head of R&D. Bayer then decided to meld its early research and development operations under one office occupied by development chief Joerg Moeller.
We’ll keep you posted on the outcome.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,100+ biopharma pros who read Endpoints News by email every day.Free Subscription